Financial Performance - The company's operating revenue for 2020 was ¥1,918,791,969.17, representing a 52.56% increase compared to ¥1,257,717,108.48 in 2019[19] - The net profit attributable to shareholders decreased by 36.04% to ¥28,028,820.43 in 2020 from ¥43,825,506.17 in 2019[19] - The total profit for the year was RMB 41.20 million, representing a year-on-year decrease of 13.17%[58] - The basic earnings per share decreased by 40.00% to ¥0.03 in 2020 from ¥0.05 in 2019[19] - The weighted average return on equity was 1.18% in 2020, down from 1.91% in 2019[19] - The gross profit margin for the pharmaceutical and chemical sector was 24.03%, down from 29.74% in the previous year[73] - The company reported a significant increase in export revenue, reaching ¥1,029,047,635.88, which is 10.29 billion, up 81.81% from the previous year[78] Cash Flow and Investments - The net cash flow from operating activities improved by 69.42%, reaching -¥28,867,357.01 in 2020, compared to -¥94,413,204.39 in 2019[19] - The total cash inflow from financing activities increased by 37.72% to 868,028,742.40 yuan in 2020[90] - The total cash outflow from investment activities decreased by 31.92% to 1,249,591,361.32 yuan in 2020[90] - The company raised a total of 1,226.74 million CNY through public offerings and private placements, with 155.25 million CNY utilized in the current period[110] - The company has a remaining balance of 562.25 million CNY in unused raised funds, which has not been allocated for any specific purpose[110] Assets and Liabilities - The total assets increased by 24.33% to ¥5,358,440,754.77 at the end of 2020, up from ¥4,309,940,220.92 at the end of 2019[19] - The net assets attributable to shareholders rose by 30.64% to ¥3,026,684,441.43 at the end of 2020, compared to ¥2,316,895,826.60 at the end of 2019[19] - Total assets included cash and cash equivalents of 748,081,305.76 yuan, accounting for 13.96% of total assets, down 5.88% from the beginning of the year[97] - Short-term borrowings increased to 409,569,595.82 yuan, accounting for 7.64% of total liabilities, a decrease of 0.49%[98] - Long-term borrowings reached 607,684,936.36 yuan, representing 11.34% of total liabilities, an increase of 3.42% due to financing for the acquisition of Brother CISA[98] Market Position and Growth - The company has established a strong position in the vitamin market, with an estimated 2020 production of 390,000 tons in China, accounting for 80% of global output, and a market value of approximately USD 3.9 billion[33] - The global flavor and fragrance market is projected to reach USD 30.2 billion in 2020, with an annual growth rate of 5.1%, driven by the Asian market's growth rate of 7.4%[34] - The company is focusing on expanding its flavor and fragrance business, with a new project for the production of 30,000 tons of natural flavors underway[30] - The company completed the acquisition of Brother CISA, enhancing its competitiveness in the chromium tanning agent market and extending its vitamin K3 production chain[32] Research and Development - The company obtained 7 invention patents and 18 utility model patents during the reporting period, enhancing its technological innovation capabilities[60] - The company has established partnerships with several domestic pharmaceutical R&D institutions, with 11 formulation products currently under development[31] - Research and development expenses amounted to 69,771,942.03 yuan in 2020, representing 3.64% of operating revenue, down from 5.60% in 2019[86] Risk Management - The company has acknowledged potential risks in its future development and has outlined corresponding countermeasures[6] - The company faces risks from macroeconomic uncertainties, industry competition, and fluctuations in raw material prices, and plans to mitigate these through strategic partnerships and innovation[129] Environmental and Social Responsibility - The company emphasizes safety management, having established a comprehensive safety management system with no major accidents reported during the reporting period[173] - The company has a significant focus on environmental protection and safety, as evidenced by its compliance with local regulations and obtaining necessary permits[67] - The company has actively engaged in social responsibility initiatives, including creating job opportunities for disabled individuals[172] Shareholder and Dividend Policy - The company plans not to distribute cash dividends or issue bonus shares[7] - The company has not made any cash dividend distributions in 2020, despite having positive net profits available for distribution[139] - The company plans to retain undistributed profits for operational and project funding needs, enhancing its risk resilience[140] Corporate Governance - The company has committed to avoid competition and related party transactions, with commitments from all directors and senior management[142] - The company has maintained a continuous audit relationship with Tianjian Accounting Firm for 14 years[149] - The company has not made any changes to its accounting policies or estimates compared to the previous year's financial report[144]

兄弟科技股份有限公司 2020 年第三季度报告全文 兄弟科技股份有限公司 2020 年第三季度报告 2020 年 10 月 1 兄弟科技股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人钱志达、主管会计工作负责人张永辉及会计机构负责人(会计主 管人员)李梨军声明：保证季度报告中财务报表的真实、准确、完整。 2 兄弟科技股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 4,725,982,609.99 | | 4,309,940,220.92 | 9.65% | | 归属于上市公司股东的净资产 | 2,497,204,781.36 | | ...

Financial Performance - The company's operating revenue for the first half of 2020 was ¥955,235,830.01, representing a 52.22% increase compared to ¥627,522,979.01 in the same period last year[17]. - The net profit attributable to shareholders of the listed company reached ¥71,573,012.44, a significant increase of 11,430.42% from a loss of ¥631,688.97 in the previous year[17]. - The net profit after deducting non-recurring gains and losses was ¥66,206,789.09, compared to a loss of ¥14,127,662.50 in the same period last year, marking a 568.63% increase[17]. - The basic earnings per share were ¥0.08, a substantial increase of 8,100.00% from a loss of ¥0.001 per share in the previous year[17]. - The total operating revenue for the reporting period reached ¥955,235,830.01, representing a year-on-year increase of 52.22%[39]. - The total profit for the first half of 2020 was ¥93,418,942.33, a substantial increase from ¥1,530,076.05 in the previous year[164]. - The company reported a basic and diluted earnings per share of ¥0.08 for the first half of 2020, compared to a loss of ¥0.001 per share in the same period of 2019[165]. - The company reported a total revenue of 2,411,271,000 RMB for the first half of 2020, reflecting a decrease of 30.34% compared to the previous period[186]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,617,685,373.34, reflecting a 7.14% increase from ¥4,309,940,220.92 at the end of the previous year[17]. - The total liabilities increased to CNY 2,352,148,919.58 as of June 30, 2020, compared to CNY 1,993,044,394.32 at the end of 2019, reflecting a growth of 18.1%[157]. - The cash and cash equivalents decreased to CNY 114,337,949.11 from CNY 260,823,078.25, a decline of 56.2%[159]. - The company's long-term borrowings rose to CNY 530,522,944.34 from CNY 341,471,393.26, marking a 55.5% increase[157]. - The total equity attributable to the parent company decreased to CNY 2,265,536,453.76 from CNY 2,316,895,826.60, a decline of 2.2%[157]. Cash Flow - The net cash flow from operating activities was -¥77,674,746.04, an improvement of 13.64% compared to -¥89,941,583.87 in the same period last year[17]. - The net cash flow from investing activities significantly decreased by 386.71% to -¥799,063,652.13, primarily due to the acquisition of Brother CISA[40]. - The net cash flow from financing activities surged by 3,192.56% to ¥283,887,078.45, mainly due to increased bank loans for the acquisition[40]. - The total cash outflow from operating activities was 871,035,740.62 CNY, compared to 641,729,732.70 CNY in the previous period, highlighting increased operational costs[171]. - The ending balance of cash and cash equivalents was 225,849,846.90 CNY, down from 304,098,361.65 CNY, reflecting a decrease in liquidity[172]. Investments and Acquisitions - The acquisition of LANXESS CISA PROPRIETARY LIMITED was completed for EUR 8.305 million, enhancing the company's product chain in vitamin K3 and chromium tanning agents[34]. - The company plans to raise CNY 1.2 billion through a private placement to fund the construction of a 30,000-ton natural flavor project and repay bank loans[34]. - The company completed the acquisition of Brother CISA, which is expected to enhance its market position in the specialty chemicals sector[53]. - The company has invested CNY 96,512,509.60 in the construction of a new project with an expected completion rate of 93.85%[55]. Research and Development - Research and development expenses increased by 20.05% to ¥33,364,923.67, reflecting the company's commitment to innovation[40]. - The company plans to increase R&D investments and improve production processes to mitigate risks and enhance efficiency[78]. - The company reported R&D expenses of CNY 33,364,923.67 for the first half of 2020, an increase from CNY 27,792,509.95 in the same period last year, reflecting a focus on innovation[162]. Market Position and Recognition - The company maintains a strong market position in vitamins and leather chemicals, with significant global market share[29]. - The company has been recognized with multiple honors, including "Zhejiang Province Famous Trademark" and "Zhejiang Export Brand," enhancing its brand reputation[29]. - The company has a robust management team with nearly 30 years of industry experience, ensuring effective strategic direction and operational efficiency[30]. Environmental Compliance - The company reported a chemical oxygen demand (COD) emission of 4.728 tons, which is within the approved limit of 52.4 tons[110]. - The ammonia nitrogen (NH3-N) emission was 0.0228 tons, significantly below the approved limit of 3.688 tons[110]. - The company has established various pollution control facilities, including a waste gas treatment facility with a capacity of 1.8 tons/hour, operational since April 15, 2020, and is currently stable[112]. - The company operates a solid waste incineration furnace with a capacity of 15 tons/day, which has been stable since its operation on August 20, 2018[113]. Risks and Challenges - The company faces risks including raw material price fluctuations, product price volatility, and industry cyclicality[4]. - The company is currently involved in a legal dispute with Zhejiang Province, with potential liabilities amounting to CNY 12 million, but it does not expect significant impact on operations[87]. - The company has not reported any significant environmental incidents or other major issues during the reporting period[116].

Financial Performance - The company's revenue for Q1 2020 was ¥458,113,413.25, representing a 46.97% increase compared to ¥311,707,146.99 in the same period last year[9] - Net profit attributable to shareholders was ¥19,849,624.40, a significant turnaround from a loss of ¥25,424,067.35 in the previous year, marking a 178.07% improvement[9] - The net profit after deducting non-recurring gains and losses was ¥19,231,391.57, up 157.88% from a loss of ¥33,227,742.47 in the same period last year[9] - The company's basic earnings per share increased to ¥0.02 from a loss of ¥0.03, reflecting a 175.96% improvement[9] - Operating revenue rose by 46.97% to ¥458,113,413.25, mainly attributed to the inclusion of Brother CISA in the consolidated financial statements[17] - Net profit reached ¥19,849,624.40, a significant turnaround from a net loss of ¥25,424,067.35 in the previous year, driven by increased product margins[17] - The company reported a total comprehensive income of -21,525,124.89 CNY for the quarter, compared to -22,043,764.14 CNY in the same quarter last year[50] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,556,715,270.27, a 5.73% increase from ¥4,309,940,220.92 at the end of the previous year[9] - The company's total assets increased to CNY 3,621,593,364.76 from CNY 3,607,778,218.95[41] - Total liabilities increased to CNY 2,327,760,551.63 from CNY 1,993,044,394.32, which is an increase of about 16.8%[37] - The company's short-term borrowings rose to CNY 557,824,893.04 from CNY 350,427,513.57, reflecting an increase of approximately 59.3%[36] - Long-term borrowings also increased to CNY 465,780,209.12 from CNY 341,471,393.26, representing a growth of about 36.5%[37] - The total equity attributable to shareholders decreased to CNY 2,228,954,718.64 from CNY 2,316,895,826.60, a decline of approximately 3.8%[38] Cash Flow - The net cash flow from operating activities was negative at -¥68,532,959.78, worsening by 60.53% compared to -¥42,691,727.13 in the same period last year[9] - Investment activities generated a net cash outflow of ¥739,395,696.34, primarily due to payments for the acquisition of Brother CISA[18] - The cash inflow from financing activities included 93,735,600.00 CNY from borrowings, showing reliance on debt financing[57] - The cash flow from financing activities resulted in a net inflow of 307,607,944.59 CNY, compared to 661,125.00 CNY in the same period last year[54] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 35,907[13] - The company reported a significant drop in cash reserves, which may impact liquidity and operational flexibility moving forward[34] Government Support and Compliance - The company received government subsidies amounting to ¥1,478,051.56 during the reporting period[10] - The company has strengthened safety measures and compliance following administrative penalties related to safety violations at its subsidiary, Brother Vitamin[19] Changes in Accounting Standards - The company has adopted new revenue and leasing standards starting in 2020, which may impact future financial reporting[58]

兄弟科技股份有限公司 2019 年年度报告全文 兄弟科技股份有限公司 2019 年年度报告 2020 年 04 月 1 兄弟科技股份有限公司 2019 年年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人钱志达、主管会计工作负责人张永辉及会计机构负责人(会计主 管人员)李梨军声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 报告期内，不存在对公司生产经营产生实质性影响的特别重大风险。公司 已在本报告中详细阐述公司在生产经营过程中可能面临的各种风险，包括原材 料价格波动风险、产品价格波动风险、汇率波动风险、行业周期性波动风险、 未决诉讼事项风险、环境保护风险、股市波动风险等，详情请查阅本报告"第 四节 经营情况讨论与分析详情请查阅本报告第四节经营情况讨论与分析中的 "第九项公司未来发展的展望"可能面对的风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | | 2 ...

Financial Performance - Net profit attributable to shareholders was ¥19,855,360.10, a significant increase of 303.86% year-on-year[7]. - Operating revenue for the reporting period was ¥270,787,798.01, down 14.20% compared to the same period last year[7]. - Basic earnings per share were ¥0.02, an increase of 277.07% compared to the same period last year[7]. - The company reported a significant increase in other receivables, rising to ¥532,082,041.53 from ¥216,387,051.96, an increase of about 146.5%[33]. - Net profit decreased by 74.54% to CNY 19,223,671.13, attributed to a decline in vitamin prices and increased operating expenses[15]. - The total comprehensive income for Q3 2019 was CNY 20,388,125.40, recovering from a loss of CNY 10,148,434.86 in the same quarter last year[40]. - The company reported a comprehensive income total of ¥18,016,634.38, down 76.5% from ¥76,560,125.95 in the previous period[48]. - The company experienced a net loss of ¥8,472,991.77 in the third quarter, compared to a net loss of ¥21,739,662.18 in the previous period[44]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥21,086,858.89, a decrease of 123.37% year-on-year[7]. - Cash and cash equivalents decreased by 66.37% to CNY 190,496,615.42 due to increased payments for goods and equipment[15]. - The net cash flow from operating activities was negative CNY 111,028,442.76, a decrease from a positive CNY 281,297,383.28 in the previous year[54]. - Cash inflow from operating activities totaled CNY 848,232,118.89, down from CNY 1,081,747,190.69 year-over-year[52]. - The cash outflow for purchasing goods and services was CNY 681,970,674.76, which increased from CNY 483,330,082.60 in the previous year[52]. - The cash flow from financing activities showed a net inflow of CNY 149,067,391.77, contrasting with a net outflow of CNY 110,589,843.36 in the previous year[55]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,703,247,621.36, an increase of 3.39% compared to the end of the previous year[7]. - Total current assets decreased to ¥1,150,760,400.22 from ¥1,442,911,202.64, a decline of approximately 20.2% year-over-year[29]. - Total non-current assets rose to ¥2,552,487,221.14 from ¥2,139,075,545.46, an increase of about 19.3%[29]. - Total liabilities increased to ¥1,410,695,615.88 from ¥1,323,115,707.05, reflecting a growth of approximately 6.6%[30]. - The company's total liabilities increased to CNY 824,310,653.74 from CNY 679,741,830.68, reflecting a rise of 21.3%[36]. - Total equity attributable to shareholders increased to ¥2,292,552,005.48 from ¥2,258,871,041.05, a rise of about 1.5%[31]. Shareholder Information - The total number of shareholders at the end of the reporting period was 39,041[11]. - The top two shareholders, Qian Zhida and Qian Zhiming, held 28.54% and 23.74% of shares respectively, both with pledged shares[11]. - The company did not engage in any repurchase transactions during the reporting period[12]. - The company repurchased 6,791,240 shares, accounting for 0.7529% of the total share capital, with a total payment of CNY 30,000,260.48[17]. Expenses - Management expenses increased by 52.51% to CNY 141,111,175.80, mainly due to costs associated with the second phase of the pharmaceutical project[15]. - Financial expenses increased by 44.19% to CNY 21,495,612.34, primarily due to increased exchange losses[15]. - Research and development expenses for Q3 2019 were CNY 16,067,279.00, a decrease of 19.4% compared to CNY 19,942,354.35 in the same period last year[38]. - Research and development expenses were ¥43,859,788.95, down 18.1% from ¥53,546,717.31 in the previous period[45]. Future Outlook - The company expects a net profit increase of over 50% for 2019, with an estimated range of CNY 43.63 million to CNY 52.36 million[19]. - The company plans to focus on market expansion and new product development to drive future growth[36].

Financial Performance - The company's operating revenue for the first half of 2019 was ¥627,522,979.01, a decrease of 17.33% compared to ¥759,092,274.55 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was -¥631,688.97, representing a decline of 100.74% from ¥85,254,103.30 in the previous year[19]. - The net cash flow from operating activities was -¥89,941,583.87, down 147.08% from ¥191,049,856.85 in the same period last year[19]. - The basic earnings per share were -¥0.001, a decrease of 101.00% compared to ¥0.1 in the previous year[19]. - The company reported a significant decline in net profit after deducting non-recurring gains and losses, which was -¥14,127,662.50, down 119.45% from ¥72,626,137.08 in the previous year[19]. - Operating profit fell to RMB 2.41 million, down 97.93% year-on-year, while net profit attributable to the parent company was a loss of RMB 0.63 million, a decrease of 100.74%[39]. - The company reported a projected net profit for the first nine months of 2019 to be between RMB 18.88 million and RMB 26.43 million, representing a year-on-year decline of over 50%[78]. - The company’s projected net profit for the first nine months of 2019 is expected to decrease by 75% to 65% compared to the same period in 2018[78]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,571,212,708.94, a slight decrease of 0.30% from ¥3,581,986,748.10 at the end of the previous year[19]. - The total liabilities at the end of the reporting period were 901.9 million yuan, indicating a stable financial position[187]. - The total current liabilities increased to ¥844,327.66 million from ¥776,176.40 million at the end of the previous year[161]. - The asset-liability ratio was 36.38%, a slight decrease of 0.56% from the previous year[148]. - The total liabilities as of June 30, 2019, were CNY 682,547,619.43, slightly up from CNY 679,741,830.68 at the end of 2018[166]. Cash Flow - The company experienced a significant decline in cash flow from operating activities, reporting a net outflow of RMB 89.94 million, a decrease of 147.08% year-on-year[42]. - The cash flow from operating activities showed a significant decline, with outflows increasing from 430,948,782.04 CNY in the first half of 2018 to 235,968,225.77 CNY in the first half of 2019[182]. - The total cash and cash equivalents at the end of the first half of 2019 were 304,098,361.65 CNY, down from 417,889,802.15 CNY at the end of the first half of 2018[180]. - Total cash inflow from investment activities was 1,123,421,764.61 CNY, while cash outflow was 1,287,599,916.54 CNY, resulting in a net cash flow of -164,178,151.93 CNY[179]. Market and Industry Conditions - The company operates in the pharmaceutical manufacturing industry, focusing on the research, production, and sales of vitamins and leather chemicals, with key products including Vitamin K3, B1, B3, and B5[27]. - The vitamin industry in China has shown signs of recovery, with certain vitamin prices rebounding since Q1 2019, despite challenges from African swine fever and trade tensions affecting demand[31]. - The leather chemicals market is undergoing consolidation, with increased pressure on smaller enterprises due to stricter environmental regulations, leading to a more competitive landscape[31]. - The company faces risks from fluctuations in raw material prices, which have significantly impacted gross profit margins and increased operational risks[80]. - The company also experiences product price volatility, which has affected its operational performance over the past two years[80]. Research and Development - The company has a robust research and development framework, participating in the formulation of national standards and holding multiple patents, reinforcing its technological leadership[35]. - Research and development expenses amounted to RMB 27.79 million, a decrease of 17.29% compared to the previous year[42]. - The company aims to enhance its technological capabilities through ongoing research and development initiatives[190]. Shareholder Information - The total number of shareholders at the end of the reporting period was 37,340[129]. - Major shareholders include Qian Zhida with a 28.54% stake and Qian Zhiming with a 23.76% stake, both of whom have pledged their shares[129]. - The controlling shareholder, Qian Zhida, holds 257,395,438 shares, accounting for 28.54% of the total share capital[130]. Environmental and Regulatory Compliance - The company has committed to enhancing environmental protection measures in response to stricter regulations, which may increase operational costs[81]. - The company has successfully passed environmental impact assessments for all construction projects by the local environmental protection bureau[112]. - The company has established emergency response plans for environmental incidents, filed with relevant authorities[112]. Future Outlook - The company is focusing on expanding its market presence and enhancing product development strategies[186]. - The overall performance guidance for the next quarter indicates a cautious optimism based on current market trends[186]. - The overall performance outlook for the remainder of 2019 remains cautious, with a focus on cost control and operational efficiency[190].

Financial Performance - The company's operating revenue for 2018 was CNY 1,415,016,689, a decrease of 9.56% compared to CNY 1,564,526,799 in 2017[16] - The net profit attributable to shareholders of the listed company was CNY 21,817,263.90, down 94.59% from CNY 403,042,721.22 in the previous year[16] - The net profit after deducting non-recurring gains and losses was a loss of CNY 10,972,814.47, a decline of 102.78% compared to CNY 394,140,234.55 in 2017[16] - Basic earnings per share dropped to CNY 0.03, a decrease of 93.62% from CNY 0.47 in the previous year[16] - Total operating revenue for 2018 was 1,415,016,689.37 yuan, a decrease of 9.56% compared to 1,564,526,799.71 yuan in 2017[44] - Revenue from the pharmaceutical and chemical sector was 1,361,454,417.03 yuan, representing 96.21% of total revenue, down 10.44% year-on-year[44] - The company's gross profit margin for vitamin products was 30.14%, a decrease of 27.70% compared to the previous year[46] - The company’s domestic sales amounted to 704,522,013.04 yuan, a decrease of 12.99% from the previous year[46] - The company’s foreign sales were 710,494,676.33 yuan, down 5.87% year-on-year[46] Cash Flow and Investments - The net cash flow from operating activities increased by 114.24% to CNY 293,094,049.65 from CNY 123,128,954.17 in 2017[16] - The net cash flow from operating activities in the first quarter was ¥117,960,913.55, indicating strong cash generation capabilities[23] - The cash flow from operating activities for the fourth quarter was notably low at ¥11,796,666.37, reflecting potential challenges in the business[23] - The net cash flow from investing activities improved by 116.30% year-on-year, totaling ¥108,918,100.80, mainly due to increased net redemptions of financial products[57] - The net cash flow from financing activities decreased by 122.75% year-on-year, resulting in a net outflow of ¥143,999,987.43, attributed to cash dividends paid to shareholders[57] - The total cash and cash equivalents increased by 171.61% year-on-year, amounting to ¥256,312,506.04[56] Assets and Liabilities - Total assets at the end of 2018 were CNY 3,581,986,748, reflecting a growth of 3.38% from CNY 3,465,002,177 at the end of 2017[18] - The net assets attributable to shareholders decreased by 1.17% to CNY 2,258,871,041 from CNY 2,285,509,056 in 2017[18] - The company's monetary funds at the end of 2018 were ¥566,475,543.60, representing 15.81% of total assets, up from 8.95% in 2017[60] - The company's fixed assets increased to ¥1,493,772,888, representing 41.70% of total assets, up from 36.19% in 2017[60] - The company's short-term borrowings were reported at ¥2,000,000, a decrease of 0.06% compared to the previous year[60] Business Development and Strategy - The company is actively advancing projects related to phenol and its derivatives, contrast agents, and catalysts, which are expected to expand its main business scope[28] - The company established a wholly-owned subsidiary, Brother Pharmaceutical, focusing on drug research, production, and sales, further diversifying its business[28] - The company is focusing on the construction of key projects, including the Vitamin B3 and B5 projects, which are expected to be operational in 2019[41] - The company plans to accelerate the construction of a strategic development base for pharmaceuticals, focusing on expanding its product chain in various fields including feed additives and pharmaceutical raw materials[82] - The company plans to explore strategic acquisition resources and establish an investment fund to support business expansion and technology development[83] Risk Management - There are no significant risks that could materially affect the company's operations during the reporting period[4] - The company faces risks from raw material price fluctuations, which have caused significant variability in product gross margins[86] - The company is exposed to product price volatility risks, which have affected its operational performance over the past two years[86] - The company is also at risk from exchange rate fluctuations, particularly affecting sales of products in international markets[86] - The company is actively monitoring potential risks and will make necessary adjustments to ensure the achievement of its 2019 operational plan[87] Shareholder Returns and Dividends - The company plans to distribute a cash dividend of CNY 1.00 per 10 shares to all shareholders[4] - The company reported a cash dividend of 89,480,142.90 yuan for 2018, representing a payout ratio of 410.13% of the net profit attributable to ordinary shareholders[93] - The total cash dividend, including other methods, amounts to 119,477,325.38 yuan, reflecting a commitment to shareholder returns while considering sustainable development needs[95] - The company has not made any adjustments to its cash dividend policy during the reporting period, adhering to its established profit distribution plan[91] Corporate Governance - The company has established a governance structure that includes a shareholders' meeting, board of directors, and supervisory board to protect shareholder rights[136] - The company maintains a strict separation from its controlling shareholder in terms of personnel, assets, and finances[188] - The company has established independent financial management and internal audit departments, ensuring no shared banking accounts with the controlling shareholder[193] - The independent directors actively participated in board meetings and provided independent opinions on various corporate matters, ensuring the protection of minority shareholders' rights[198] Environmental and Social Responsibility - The company emphasizes its commitment to social responsibility and environmental protection[136] - The company has invested in environmental protection and energy conservation, enhancing its sustainable development strategy[138] - The company has achieved compliance in all monitored pollutants, including ammonia nitrogen and sulfur dioxide, with emissions below regulatory limits[142] - The company actively participates in social welfare activities, including providing job opportunities for disabled individuals[139] Employee Management and Development - The company employed a total of 2,202 staff, with 1,311 in production, 336 in technical roles, and 62 in sales[181] - The company has established a performance evaluation mechanism to enhance employee execution and responsibility awareness[182] - In 2018, the company implemented a comprehensive training plan to improve employee skills and align with strategic goals[184]

证券代码：002562 证券简称：兄弟科技 公告编号：2019-040 兄弟科技股份有限公司 关于举行投资者接待日活动的公告 | --- | --- | |----------------------------------------|----------------------------------------------------------------------------------| | 虚假记载、误导性陈述或重大遗漏。 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 | | 兄弟科技股份有限公司（以下简称"公司"） | 2018 年年度报告及摘要已于 2019年4月29 | | | 日披露，为便于广大投资者深入全面地了解公司情况，公司将举办投资者接待日活动，现将 | | 有关事项公告如下： | | | 一、接待日 | | | 2019年5月20 日（星期一） | | | 二、接待时间 | | | 接待日当日上午 9:30-11:30 | | | 三、接待地点 | | | 浙江省海宁市海洲街道学林街1号 | 兄弟科技股份有限公司会议室 | | 四、预约方式 | | | 拟 ...

Financial Performance - The company's operating revenue for Q1 2019 was ¥311,707,146.99, a decrease of 25.52% compared to ¥418,535,032.58 in the same period last year[7] - The net profit attributable to shareholders was a loss of ¥25,424,067.35, representing a decline of 135.11% from a profit of ¥72,403,731.75 in the previous year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥33,227,742.47, down 146.60% from ¥71,298,551.27 year-on-year[7] - Basic and diluted earnings per share were both -¥0.03, a decline of 123.08% from ¥0.13 in the previous year[7] - The total comprehensive income for Q1 2019 was a loss of CNY 27,090,150.39, compared to a comprehensive income of CNY 72,047,665.01 in the same period last year[37] - The total profit for Q1 2019 was a loss of CNY 23,000,818.70, compared to a profit of CNY 88,658,785.50 in the same period last year[36] Cash Flow and Liquidity - The net cash flow from operating activities was a negative ¥42,691,727.13, a decrease of 136.19% compared to ¥117,960,913.55 in the same period last year[7] - Cash and cash equivalents decreased by 43.56% to ¥319,721,036.96 from ¥566,475,543.62, primarily due to the purchase of financial products with raised funds[15] - The cash flow from operating activities showed a decrease, with cash received from sales of goods and services at CNY 235,791,629.54, down from CNY 367,901,689.70 in the previous year[43] - The total cash and cash equivalents decreased by 246,754,506.66 CNY during the period, compared to a decrease of 64,198,850.90 CNY in the previous period[45] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,585,655,908.90, a slight increase of 0.10% from ¥3,581,986,748.10 at the end of the previous year[7] - The total liabilities increased to CNY 726,470,299.73 from CNY 679,741,830.68, indicating a rise in financial obligations[32] - The company's equity decreased to CNY 2,290,716,908.21 from CNY 2,312,760,672.35, reflecting a decline in retained earnings[33] - Total assets amounted to CNY 3,581,986,748.10, with non-current assets at CNY 2,139,075,545.46[52] Operational Costs and Expenses - Total operating costs increased to CNY 342,639,092.00, up from CNY 331,543,081.00, reflecting a rise in operating costs[34] - The gross profit margin decreased due to an increase in operating costs, which rose to CNY 86,856,225.08 from CNY 70,802,798.71, representing a year-over-year increase of approximately 22.67%[39] - Research and development expenses decreased to CNY 14,327,262.53, down from CNY 15,353,395.51, indicating a focus on cost management[34] - The company's net profit margin was impacted, with a significant increase in financial expenses to CNY 11,972,068.31 from CNY 24,529,513.93 in the previous period[34] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,520[11] - The company repurchased a total of 6,790,640 shares, accounting for 0.7737% of the total share capital, with a total payment of ¥29,997,182.48[16] Future Outlook - The company expects a net profit of -¥25,576,200.00 for the first half of 2019, compared to a net profit of ¥85,254,100.00 in the same period of 2018, due to significant price declines in the vitamin market[18] Other Information - The company executed a new accounting standard change, impacting the financial reporting[55] - The first quarter report was not audited, which may affect the reliability of the financial data presented[56] - The company has not disclosed any new product developments or market expansion strategies in this report[55] - There were no significant mergers or acquisitions reported during this quarter[55]